Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Source : https://www.cureus.com/articles/61261-atrial-fibrillation-as-a-possible-adverse-reaction-to-evolocumab

Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease....

Effect of More Intensive LDL-C–Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis

Source : https://doi.org/10.1016/j.clinthera.2021.04.019

Management of Dyslipidemia in Patients with Diabetes - touchENDOCRINOLOGY

Source : https://doi.org/10.17925/USE.2011.07.01.40

In association with the global spread of abdominal adiposity, the worldwide prevalence of type 2 diabetes continues to increase.1 This is one of the pivotal factors underscoring the projection that...

ANKS1A genotype predicts cardiovascular events in patients with familial hypercholesterolemia

Source : https://doi.org/10.1016/j.jacl.2021.05.006

Founder effects facilitate the use of a genotyping‐based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia

Source : https://onlinelibrary.wiley.com/doi/10.1111/joim.13287

P. Benedek , H. Jiao , J. Kere , M. Eriksson , B.